The second psychedelics program was released because it’s highly material and had to be made public once IHL and Monash University signed the agreement. It’s a fantastic development that every shareholder should be excited about and it reduces the risk of your investment because there’s another program to develop.
The OSA release is pending an independent audit from a third party. The company clearly believes it’s due this quarter (it’s currently only the 7th March btw) but it’s still subject to the timing of a third party.
It’s okay to be nervous but some of you guys are paralyzed by your own analysis.
IHL Price at posting:
56.5¢ Sentiment: Buy Disclosure: Held
